TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Can-Fite BioPharma ( (CANF) ) is now available.
On November 20, 2025, Can-Fite BioPharma Ltd. announced that its erectile dysfunction treatment, CF602, received a Notice of Allowance for a patent in Brazil. This patent expands CF602’s intellectual property protection beyond the U.S. and Europe, addressing a significant market need for diabetic patients and non-responders to existing ED drugs. CF602, an A3 adenosine receptor modulator, has shown promising results in preclinical studies, potentially offering an alternative to current ED treatments.
The most recent analyst rating on (CANF) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on Can-Fite BioPharma stock, see the CANF Stock Forecast page.
Spark’s Take on CANF Stock
According to Spark, TipRanks’ AI Analyst, CANF is a Underperform.
Can-Fite BioPharma’s stock score is primarily impacted by its weak financial performance and bearish technical indicators. The lack of profitability and absence of valuation metrics further contribute to the low score. Strategic improvements are necessary to enhance financial stability and investor confidence.
To see Spark’s full report on CANF stock, click here.
More about Can-Fite BioPharma
Can-Fite BioPharma Ltd. is a biotechnology company focused on developing proprietary small molecule drugs targeting oncological and inflammatory diseases. The company’s lead drug candidates include Piclidenoson for psoriasis, Namodenoson for liver cancer and other cancers, and CF602 for erectile dysfunction. Can-Fite operates in multi-billion-dollar markets with a strong emphasis on safety, having tested its drugs in over 1,600 patients.
Average Trading Volume: 5,938,733
Technical Sentiment Signal: Sell
Current Market Cap: $15.63M
Find detailed analytics on CANF stock on TipRanks’ Stock Analysis page.